Previous 10 | Next 10 |
- Suprachoroidal Space injections can be easily conducted in physicians’ offices as a potentially useful method of ocular distribution of drug to target back of the eye diseases - ALPHARETTA, Ga., July 31, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a...
ALPHARETTA, Ga., July 18, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple oral presentations on Clearsi...
Clearside Biomedical (NASDAQ: CLSD ) has entered into a worldwide licensing agreement with Aura Biosciences for the use of its Suprachoroidal Space (SCS) Microinjector to deliver Aura’s drug candidates into the SCS for the treatment of certain ocular cancers, including choroidal mel...
ALPHARETTA, Ga., July 09, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced its entry into a worldwide licensing agreement w...
ALPHARETTA, Ga., June 11, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Med...
The following slide deck was published by Clearside Biomedical, Inc. in conjunction with this Read more ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Retailers cap off the Q1 earnings season in style as Target (TGT), Best Buy (BBY), ...
ALPHARETTA, Ga., May 15, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Brion Raymond, Chief Com...
Clearside Biomedical, Inc. (CLSD) Q1 2019 Earnings Conference Call May 08, 2019, 08:30 AM ET Company Participants Jenny Kobin - IR George Lasezkay - Interim CEO Thomas Ciulla - Chief Medical Officer Brion Raymond - Chief Commercial Officer Charlie Deignan - CFO Conference ...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...